Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load

Prior treatment

• Not having received more than three previous lines of antiretroviral treatment
• Have diabetes mellitus on treatment with SGLT2, GLP1 or plioglitazone of less than 6 months duration.
• Any previous physical or mental condition (such as habitual drug use) that the investigator believes may interfere with the patient's ability to comply with the study protocol.
• Prior history of Rilpivirine use of any duration.

Other illness

• Have an HIV viral load \< 50 copies/ml for at least the last 6 months, 1 blip below 500 copies/ml is allowed during this period.
• Have an ultrasound-diagnosed fatty liver metabolic disease or a CAP (Controlled Attenuation Parameter®) measurement \> 238 dB/m with an IQR \< 30 dB/m.
• Have an fatty liver metabolic disease with some degree of fibrosis diagnosed by ET (Fibroscan®) \> 5.2 kPa. In patients in whom ET is not possible, have a FIB-4 \>1.3.
• Have chronic HBV infection (presence of HBsAg+) or HCV (detectable HCV viral load). Patients with past treated HCV are also not allowed to be included (does not include patients with spontaneously resolved HCV infection).
• Have a history of alcohol abuse
• Have chronic decompensated liver disease, defined as any of the following: presence of encephalopathy, ascites, coagulopathy, oesophageal or gastric varices, or persistent jaundice.

Other

• No resistance mutations that compromise the efficacy of Rilpivirine, Dolutegravir, Tenofovir (TDF and/or TAF) or Emtricitabine.
• Be able to understand and comply with the requirements and instructions of the protocol.
• Understanding long-term commitment to study
• Acceptance of their participation in the study by signing an informed consent form.
• Harmful alcohol consumption, defined as \>30 grams of alcohol per day in men and \>20 grams of alcohol per day in women.
• Pregnancy or breastfeeding at the screening visit or at any time during the study or intention to become pregnant during the study period.

• Patients over 18 years of age with HIV infection who have never received antiretroviral treatment with Rilpivirine.
• Have a stable ART pattern for at least the last 6 month